To apply both assays within their designated specifications, we evaluated the tests on a cohort of ER+, HER2−, TNM Stage I and II breast cancers below 5 cm in diameter with up to three positive lymph nodes. The gene discussed is ERBB2; the disease is breast carcinoma.